Literature DB >> 8299088

Axillary lymph node dissection for T1a breast carcinoma. Is it indicated?

M J Silverstein1, E D Gierson, J R Waisman, G M Senofsky, W J Colburn, P Gamagami.   

Abstract

BACKGROUND: Axillary dissection has been a routine part of breast cancer treatment for more than 100 years. Axillary node involvement is the single most important prognostic variable in patients with breast cancer. Recently, routine node dissection has been eliminated for intraductal carcinoma because so few patients had positive nodes. With the availability of numerous histologic prognosticators and the development of new immunochemical prognostic indicators, it is time to consider eliminating routine node dissection for lesions more advanced than duct carcinoma in situ (DCIS) but with extremely low likelihood of axillary involvement.
METHODS: Axillary node positivity, disease-free survival, and breast cancer-specific survival were determined for six breast cancer subgroups by T category: Tis (DCIS), T1a, T1b, T1c, T2, and T3.
RESULTS: Nodal positivity for DCIS was 0%; for T1a lesions, 3%. A large increase in nodal positivity was seen in lesions larger than 5 mm. (T1b, 17%; T1c, 32%; T2, 44%; T3, 60%). The rate of nodal positivity was statistically different as each T category was compared with the next more advanced T category. The disease-free survival and breast cancer-specific survival decreased with every increment in T value.
CONCLUSIONS: Axillary node positivity increases as the size of the invasive component increases and is an excellent predictor of DSF and breast cancer-specific survival. Consideration should be given to eliminating axillary node dissection for T1a lesions because of the low yield of positive nodes. Axillary node dissection should be performed routinely for T1b lesions and larger.

Entities:  

Mesh:

Year:  1994        PMID: 8299088     DOI: 10.1002/1097-0142(19940201)73:3<664::aid-cncr2820730326>3.0.co;2-s

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

1.  Three dimensional staging of breast cancer.

Authors:  I L Wapnir; D E Wartenberg; R S Greco
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

2.  Complications of level I and II axillary dissection in the treatment of carcinoma of the breast.

Authors:  D F Roses; A D Brooks; M N Harris; R L Shapiro; J Mitnick
Journal:  Ann Surg       Date:  1999-08       Impact factor: 12.969

3. 

Authors:  P Schäfer
Journal:  Arch Gynecol Obstet       Date:  1995-12       Impact factor: 2.344

4. 

Authors:  J C Rageth
Journal:  Arch Gynecol Obstet       Date:  1995-12       Impact factor: 2.344

5.  An analysis of breast cancer in Hungary: experience of the National Institute of Oncology, Budapest.

Authors:  I Besznyák; E Svastics
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

6.  Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

Authors:  I C Smith; K N Ogston; P Whitford; F W Smith; P Sharp; M Norton; I D Miller; A K Ah-See; S D Heys; J A Jibril; O Eremin
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

7.  How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?

Authors:  Min Yi; Funda Meric-Bernstam; Merrick I Ross; Jeri S Akins; Rosa F Hwang; Anthony Lucci; Henry M Kuerer; Gildy V Babiera; Michael Z Gilcrease; Kelly K Hunt
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

8.  Reassessing the role of axillary lymph-node dissection in patients with early-stage breast cancer.

Authors:  Jeff Marschall; Patrik Nechala; Patrick Colquhoun; Rajni Chibbar
Journal:  Can J Surg       Date:  2003-08       Impact factor: 2.089

Review 9.  FDG-PET for axillary lymph node staging in primary breast cancer.

Authors:  Flavio Crippa; Alberto Gerali; Alessandra Alessi; Roberto Agresti; Emilio Bombardieri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-05       Impact factor: 9.236

10.  Correlation of Various Biomarkers with Axillary Nodal Metastases: Can a Panel of Such Biomarkers Guide Selective Use of Axillary Surgery in T1 Breast Cancer?

Authors:  Tufale A Dass; Sharma Rakesh; K Patil Prakash; Chandraveer Singh
Journal:  Indian J Surg Oncol       Date:  2015-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.